- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical development of CAR T cell therapy in China: 2020 update
Authors
Keywords
-
Journal
Cellular & Molecular Immunology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-09-30
DOI
10.1038/s41423-020-00555-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Early response observed in pediatric patients with relapsed/refractory Burkitt lymphoma treated with chimeric antigen receptor T cells
- (2020) Wenqun Zhang et al. BLOOD
- Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial
- (2020) Yang Liu et al. CYTOTHERAPY
- Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo
- (2020) Colby R. Maldini et al. NATURE MEDICINE
- Evaluation of a Fully Human, Hepatitis B Virus-Specific Chimeric Antigen Receptor in an Immunocompetent Mouse Model
- (2019) Marvin M. Festag et al. MOLECULAR THERAPY
- CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response
- (2019) Nicholas F. Kuhn et al. CANCER CELL
- Early and late hematologic toxicity following CD19 CAR-T cells
- (2019) Shalev Fried et al. BONE MARROW TRANSPLANTATION
- Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy
- (2019) Huiwen Jiang et al. ANNALS OF HEMATOLOGY
- CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia
- (2019) Jing Pan et al. LEUKEMIA
- A safe and potent anti-CD19 CAR T cell therapy
- (2019) Zhitao Ying et al. NATURE MEDICINE
- CAR T cells drive out B cells in SLE
- (2019) Jessica McHugh Nature Reviews Rheumatology
- Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma
- (2019) Jie Xu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes
- (2019) Michel Tenspolde et al. JOURNAL OF AUTOIMMUNITY
- IFN-γ and TNF-α aggravate endothelial damage caused by CD123-targeted CAR T cell
- (2019) Yao Sun et al. OncoTargets and Therapy
- Anti‐CD19 chimeric antigen receptor‐modified T‐cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B‐cell acute lymphoblastic leukemia: An open‐label pragmatic clinical trial
- (2019) Huiwen Jiang et al. AMERICAN JOURNAL OF HEMATOLOGY
- Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells
- (2019) Zhitao Gao et al. Journal of Genetics and Genomics
- Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model
- (2019) Kim Anthony-Gonda et al. Science Translational Medicine
- Shortening the ex vivo culture of CD19‐specific CAR T‐cells retains potent efficacy against acute lymphoblastic leukemia without CAR T‐cell‐related encephalopathy syndrome or severe cytokine release syndrome
- (2019) Sanfang Tu et al. AMERICAN JOURNAL OF HEMATOLOGY
- Early Response Observed in Pediatric Patients with Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma Treated with Sequential Chimeric Antigen Receptor T Cells
- (2019) Wenqun Zhang et al. BLOOD
- Efficacy and Safety of CAR19/22 T-cell "Cocktail" Therapy in Patients with Refractory/ Relapsed B-Cell Malignancies
- (2019) Na Wang et al. BLOOD
- Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL
- (2019) Jing Pan et al. BLOOD
- CD56–chimeric antigen receptor T-cell therapy for refractory/recurrent rhabdomyosarcoma
- (2019) Chiyi Jiang et al. MEDICINE
- CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors
- (2019) Linchun Jin et al. Nature Communications
- A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial
- (2019) Zhiling Yan et al. Lancet Haematology
- Donor-Derived CD123-Targeted CAR T Cell Serves as a RIC Regimen for Haploidentical Transplantation in a Patient With FUS-ERG+ AML
- (2019) Sun Yao et al. Frontiers in Oncology
- Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR-T containing either CD28 or 4-1BB
- (2018) Shiqi Li et al. BRITISH JOURNAL OF HAEMATOLOGY
- A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia
- (2018) Jianyu Weng et al. Journal of Hematology & Oncology
- Turning the tables on cytomegalovirus: targeting viral Fc receptors by CARs containing mutated CH2–CH3 IgG spacer domains
- (2018) Julia Proff et al. Journal of Translational Medicine
- IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor
- (2018) Keishi Adachi et al. NATURE BIOTECHNOLOGY
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
- (2018) Jae H. Park et al. NEW ENGLAND JOURNAL OF MEDICINE
- Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System
- (2018) Mauro P. Avanzi et al. Cell Reports
- Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors
- (2018) Paris Kosti et al. Frontiers in Immunology
- CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial
- (2018) Yao Wang et al. OncoImmunology
- Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
- (2018) Jun Gong et al. Journal for ImmunoTherapy of Cancer
- Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
- (2018) Kris M. Mahadeo et al. Nature Reviews Clinical Oncology
- First CAR to Pass the Road Test: Tisagenlecleucel's Drive to FDA Approval
- (2018) Mark B. Geyer CLINICAL CANCER RESEARCH
- The landscape of CAR T-cell therapy in the United States and China: A comparative analysis
- (2018) Lijuan Gou et al. INTERNATIONAL JOURNAL OF CANCER
- A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
- (2018) Wan-Hong Zhao et al. Journal of Hematology & Oncology
- Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma
- (2018) Jinhuan Xu et al. Journal of Hematology & Oncology
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
- (2018) Frederick L Locke et al. LANCET ONCOLOGY
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma
- (2017) Kai-chao Feng et al. Journal of Hematology & Oncology
- Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA + Metastatic Colorectal Cancers
- (2017) Chengcheng Zhang et al. MOLECULAR THERAPY
- Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells
- (2017) Malika Hale et al. MOLECULAR THERAPY
- CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
- (2017) Terry J Fry et al. NATURE MEDICINE
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
- (2017) Sattva S. Neelapu et al. Nature Reviews Clinical Oncology
- Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
- (2017) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions
- (2017) C A van der Weyden et al. Blood Cancer Journal
- Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers
- (2017) Kaichao Feng et al. Protein & Cell
- Toxicities of chimeric antigen receptor T cells: recognition and management
- (2016) Jennifer N. Brudno et al. BLOOD
- Potent Anti-leukemia Activities of Chimeric Antigen Receptor–Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia
- (2016) Yongxian Hu et al. CLINICAL CANCER RESEARCH
- Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial
- (2016) Chun-Meng Wang et al. CLINICAL CANCER RESEARCH
- Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors
- (2016) Manisha H. Shah et al. INVESTIGATIONAL NEW DRUGS
- Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia
- (2016) Bo Cai et al. Journal of Hematology & Oncology
- Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
- (2016) Yongxian Hu et al. Journal of Hematology & Oncology
- Precision medicine for autoimmune disease
- (2016) Lucienne Chatenoud NATURE BIOTECHNOLOGY
- Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells
- (2016) Fengtao You et al. Science China-Life Sciences
- Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer
- (2016) Kaichao Feng et al. Science China-Life Sciences
- Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
- (2016) D. T. Teachey et al. Cancer Discovery
- Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma
- (2016) Ahmed Omar Kaseb et al. Oncotarget
- CD133, Selectively Targeting the Root of Cancer
- (2016) Jörg Schmohl et al. Toxins
- Bioactivity and Safety of IL13R 2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
- (2015) C. E. Brown et al. CLINICAL CANCER RESEARCH
- Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein
- (2015) Giuseppe A Sautto et al. GUT
- Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
- (2015) Nabil Ahmed et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of CD33-directed Chimeric Antigen Receptor-modified T Cells in One Patient With Relapsed and Refractory Acute Myeloid Leukemia
- (2015) Quan-shun Wang et al. MOLECULAR THERAPY
- Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia
- (2015) Hanren Dai et al. OncoImmunology
- Immune Escape Mechanisms as a Guide for Cancer Immunotherapy
- (2014) G. L. Beatty et al. CLINICAL CANCER RESEARCH
- Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells
- (2014) Yao Wang et al. CLINICAL IMMUNOLOGY
- IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia
- (2014) H J Pegram et al. LEUKEMIA
- Suppression of Murine Colitis and its Associated Cancer by Carcinoembryonic Antigen-Specific Regulatory T Cells
- (2014) Dan Blat et al. MOLECULAR THERAPY
- Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection
- (2014) P. R. Kumaresan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
- (2014) A Ehninger et al. Blood Cancer Journal
- Mesothelin Overexpression Is a Marker of Tumor Aggressiveness and Is Associated with Reduced Recurrence-Free and Overall Survival in Early-Stage Lung Adenocarcinoma
- (2013) S. S. Kachala et al. CLINICAL CANCER RESEARCH
- B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
- (2013) R. O. Carpenter et al. CLINICAL CANCER RESEARCH
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- (2013) Stephan A. Grupp et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1- and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses
- (2013) V. D. Fedorov et al. Science Translational Medicine
- Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
- (2013) G. L. Beatty et al. Cancer Immunology Research
- Gene Therapy of Malignant Solid Tumors by Targeting erbB2 Receptors and by Activating T Cells
- (2012) Wang-Xiong Hu et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells
- (2012) Christopher C Kloss et al. NATURE BIOTECHNOLOGY
- Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
- (2011) C. U. Louis et al. BLOOD
- Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
- (2011) R. J. Brentjens et al. BLOOD
- IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression
- (2011) M. Chmielewski et al. CANCER RESEARCH
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- (2011) David L. Porter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in Humans
- (2010) Michael C. Jensen et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
- (2010) J. N. Kochenderfer et al. BLOOD
- Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas
- (2010) Ymera Pignochino et al. BMC CANCER
- High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma
- (2010) X.-R. Yang et al. GUT
- Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma
- (2010) Keisuke Kohga et al. JOURNAL OF HEPATOLOGY
- The membrane-bound mucins: From cell signalling to transcriptional regulation and expression in epithelial cancers
- (2009) Nicolas Jonckheere et al. BIOCHIMIE
- Targeting CD133 antigen in cancer
- (2009) Gabriella Ferrandina et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
- (2008) C. Gravalos et al. ANNALS OF ONCOLOGY
- EGFR Antagonists in Cancer Treatment
- (2008) Fortunato Ciardiello et al. NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started